Kezar Life Sciences Files 8-K
Ticker: KZR · Form: 8-K · Filed: Sep 30, 2024 · CIK: 1645666
| Field | Detail |
|---|---|
| Company | Kezar Life Sciences, INC. (KZR) |
| Form Type | 8-K |
| Filed Date | Sep 30, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, financial-statements
Related Tickers: KZR
TL;DR
Kezar Life Sciences filed an 8-K on 9/30/24. Details on 'other events' TBD.
AI Summary
Kezar Life Sciences, Inc. filed an 8-K on September 30, 2024, reporting other events and financial statements. The filing does not contain specific financial figures or details about the 'other events' in the provided text.
Why It Matters
This filing indicates a regulatory update from Kezar Life Sciences, Inc. The specific nature of the 'other events' is not detailed in the provided excerpt.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and financial statements, with no immediate indication of significant negative developments in the provided text.
Key Players & Entities
- Kezar Life Sciences, Inc. (company) — Registrant
- September 30, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 4000 Shoreline Court, Suite 300 (address) — Principal Executive Offices
- South San Francisco, California (location) — Principal Executive Offices City and State
FAQ
What specific 'Other Events' are being reported by Kezar Life Sciences, Inc. in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the 'Other Events' being reported.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 30, 2024.
What is the principal executive office address for Kezar Life Sciences, Inc.?
The principal executive office address for Kezar Life Sciences, Inc. is 4000 Shoreline Court, Suite 300, South San Francisco, California, 94080.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the Standard Industrial Classification code for Kezar Life Sciences, Inc.?
The Standard Industrial Classification code for Kezar Life Sciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 431 words · 2 min read · ~1 pages · Grade level 10.2 · Accepted 2024-09-30 08:36:09
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value KZR The Nasdaq Stock Mark
Filing Documents
- kzr-20240930.htm (8-K) — 39KB
- kzr-ex99_1.htm (EX-99.1) — 16KB
- 0000950170-24-110177.txt ( ) — 167KB
- kzr-20240930.xsd (EX-101.SCH) — 23KB
- kzr-20240930_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On September 30, 2024, Kezar Life Sciences, Inc. issued a press release providing an update on its PALIZADE Phase 2 clinical trial. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated September 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEZAR LIFE SCIENCES, INC. Date: September 30, 2024 By: /s/ Marc L. Belsky Marc L. Belsky Chief Financial Officer and Secretary